从事抗肿瘤药物药理学研究，致力于药物联用策略和创新药物发现工作。聚焦致癌性RAS突变等肿瘤驱动基因，系统解析其驱动肿瘤信号网络重塑及恶性演进的新机制，并以此为基础，建立细胞内药物与靶标结合的创新药物发现和评价体系。

1. Deep learning-based discovery of tetrahydrocarbazoles as broad-spectrum antitumor agents and click-activated strategy for targeted cancer therapy. Liu X#, Lu Y#, Chen Q#, Yang M, Li S, Sun H, Liu X, Yan J, Li L, Xiang N, Lu Y, Geng Q, Deng Y, Wang B, Jin J*, Zhao H, Pan X, Al-Harrasi A, Du T*, Song W*, Wang X*. Acta Pharm Sin B, 2026.
2. Mitochondrial uncouplers inhibit oncogenic E2F1 activity and prostate cancer growth. Hawsawi O#, Xue W#, Du T#, Guo M#, Yu X, Zhang M, Hoffman P S, Bollag R, Li J, Zhou J, Wang H, Zhang J, Fu Z, Chen X, Yan C*. Cell Rep Med, 2025.
3. One-Shot rational design of covalent drugs with CovalentLab. Xue X#, Liu X#, Liu X#, Sun H, Li S, Chen K, Xu H, Li L, Mao C, Yan J, Yang P, Wang B, Hou T*, Du T*, Wang X*. JACS Au, 2025.
4. Discovery of potent and selective STAT3 inhibitors against triple-negative breast cancer. Wang R#, Li L#, Zhao C, Yang Y, Li X, Yang B, Du T*, Song P*, Li L*. Eur J Med Chem, 2025.
5. Re-expression of epigenetically silenced PTPRR by histone acetylation sensitizes RAS-mutant lung adenocarcinoma to SHP2 inhibition. Du T#, Hu X#, Hou Z, Wang W, You S, Wang M, Ji M*, Xue N*, Chen X*. Cell Mol Life Sci, 2024.
6. Target fishing and mechanistic insights of the natural anticancer drug candidate chlorogenic acid. Wang Q#, Du T#, Zhang Z, Zhang Q, Zhang J, Li W, Jiang J D, Chen X*, Hu H*. Acta Pharm Sin B, 2024.
7. Design, Synthesis, and Bioevaluation of Novel Reversibly Photoswitchable PI3K Inhibitors Based on Phenylazopyridine Derivatives toward Light-Controlled Cancer Treatment. Zhang Y#, Deng J#, Tian H#, Qi H, Xiong T, Lin S, Dong Y, Luo L, Wu D, Zhang K, Ji M, Du T*, Sheng L*, Chen X, Xu H*. J Med Chem, 2024.